Pneumococcal Glycoconjugate Compositions With Broader Serotype Coverage

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current pneumococcal vaccines like PREVNAR 13® do not provide adequate coverage against emerging serotypes and are susceptible to antigenic interference, necessitating the development of immunogenic compositions that can protect against additional Streptococcus pneumoniae serotypes while minimizing immune interference.

Innovation Solution

Development of immunogenic compositions comprising glycoconjugates from serotypes 15B, 22F, 33F, 12F, 10A, and 8, along with a kit containing these glycoconjugates and additional serotypes, allowing for simultaneous, concurrent, or sequential administration to induce an immune response against a broader range of pneumococcal serotypes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If existing pneumococcal vaccines like PREVNAR 13 are used, then protection against covered serotypes is achieved, but coverage against emerging serotypes is inadequate

Engineering Contradiction:

Improvecoverage against emerging serotypesVSAvoidprotection effectiveness

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The vaccine composition is segmented into multiple distinct glycoconjugate components, each targeting specific pneumococcal serotypes. The composition includes glycoconjugates from serotypes 15B, 22F, 33F, 12F, 10A, and 8, allowing the vaccine to address multiple emerging serotypes simultaneously while maintaining reliable protection through targeted immunogenicity for each serotype group

Inventive Principle:

Principle #1Segmentation

2Adaptability or versatility

If broader serotype coverage is added to vaccines, then protection against more serotypes is achieved, but antigenic interference increases

Engineering Contradiction:

Improveserotype coverage breadthVSAvoidantigenic interference

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

Each glycoconjugate component in the composition is specifically designed with local quality characteristics tailored to its target serotype. The composition includes glycoconjugates from serotypes 15B, 22F, 33F, 12F, 10A, and 8, where each component maintains its unique antigenic properties while contributing to overall serotype coverage, thereby minimizing antigenic interference through differentiated local immunogenicity

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The vaccine composition employs a composite structure combining multiple glycoconjugate materials from different serotypes. This composite approach integrates glycoconjugates from serotypes 15B, 22F, 33F, 12F, 10A, and 8 into a unified formulation that achieves broad serotype coverage while the diverse material composition helps reduce antigenic interference through complementary rather than competitive immune responses

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS20260048112A1Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof

Publication Date: 2026.02.19 PFIZER INC

AI summary

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.